Empagliflozinによる心外膜脂肪前駆細胞の分化/成熟抑制と傍分泌効果の改善
Abstract
HIGHLIGHTS SGLT2 is primarily expressed in human preadipocytes in the epicardial adipose tissue.The expression levels of SGLT2 diminish as the preadipocytes are differentiated to mature adipocytes.The SGLT2 inhibitor empagliflozin improves the paracrine secretome profiles, potentially leading to the cardioprotective effect.IL6 may be a critical adipokine that is regulated by SGLT2 inhibitors.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.